Inibio key facts
as of Oct 2026- Operator of a biomedical company intended to make botulinum toxin.
- Inibio is valued at approximately $129.2M as of Oct 2026 (last reported valuation).
- Notable investors include J&P Private Equity, GC Biopharma.
- Status: Privately Held (backing).
Inibio's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·Watch Inibio: the Monday email on marks, rounds and moves
Inibio funding rounds
No funding rounds for Inibio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Inibio
2Inibio valuation
Inibio's last reported valuation was $129 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
Inibio investors
2 investors are on record for Inibio, including J&P Private Equity and GC Biopharma.
About Inibio
Operator of a biomedical company intended to make botulinum toxin. The company specializes in medical aesthetics and develops Botox based on plant-derived ingredients, providing customers with Botox that offers proven stability and efficacy, enabling healthcare providers and global partners to access high-quality, compliant products for skin health and therapeutic applications.
- Sector
- Healthcare
- HQ
- Bucheon, South Korea
- Founded
- 2017
- Employees
- 135
- Website
- inibio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.